• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Biochemistry . Rimantadine Binds to and Inhibits the Influenza A M2 Proton Channel without Enantiomeric Specificity

tetano

Editor, Senior Moderator
Biochemistry


. 2021 Aug 3.
doi: 10.1021/acs.biochem.1c00437. Online ahead of print.
Rimantadine Binds to and Inhibits the Influenza A M2 Proton Channel without Enantiomeric Specificity


Jessica L Thomaston[SUP] 1 [/SUP], Marley L Samways[SUP] 2 [/SUP], Athina Konstantinidi[SUP] 3 [/SUP], Chunlong Ma[SUP] 4 [/SUP], Yanmei Hu[SUP] 4 [/SUP], Hannah E Bruce Macdonald[SUP] 5 [/SUP], Jun Wang[SUP] 4 [/SUP], Jonathan W Essex[SUP] 2 [/SUP], William F DeGrado[SUP] 1 [/SUP], Antonios Kolocouris[SUP] 3 [/SUP]



Affiliations

Abstract

The influenza A M2 wild-type (WT) proton channel is the target of the anti-influenza drug rimantadine. Rimantadine has two enantiomers, though most investigations into drug binding and inhibition have used a racemic mixture. Solid-state NMR experiments using the full length-M2 WT have shown significant spectral differences that were interpreted to indicate tighter binding for (R)- vs (S)-rimantadine. However, it was unclear if this correlates with a functional difference in drug binding and inhibition. Using X-ray crystallography, we have determined that both (R)- and (S)-rimantadine bind to the M2 WT pore with slight differences in the hydration of each enantiomer. However, this does not result in a difference in potency or binding kinetics, as shown by similar values for k[SUB]on[/SUB], k[SUB]off[/SUB], and K[SUB]d[/SUB] in electrophysiological assays and for EC[SUB]50[/SUB] values in cellular assays. We concluded that the slight differences in hydration for the (R)- and (S)-rimantadine enantiomers are not relevant to drug binding or channel inhibition. To further explore the effect of the hydration of the M2 pore on binding affinity, the water structure was evaluated by grand canonical ensemble molecular dynamics simulations as a function of the chemical potential of the water. Initially, the two layers of ordered water molecules between the bound drug and the channel's gating His37 residues mask the drug's chirality. As the chemical potential becomes more unfavorable, the drug translocates down to the lower water layer, and the interaction becomes more sensitive to chirality. These studies suggest the feasibility of displacing the upper water layer and specifically recognizing the lower water layers in novel drugs.
 
Back
Top Bottom